Fem Glandular and Tissue Aid
Brand Names: Fem Repair Non-Preg
Methodology & AI Transparency ⓘ
Fem Glandular and Tissue Aid Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Clinicians prescribe Fem Glandular and Tissue Aid (14 [hp_X]/mL / 6 [hp_X]/mL Liquid; NDC 64616-090) as a oral-route copper absorption inhibitor formulation manufactured/labeled by Vitality Works, Inc.
- 2 Real-world patient consensus: Real-world cohort score of 89% across 10 de-identified Fem Glandular and Tissue Aid entries.
- 3 Typical cash cost range: 30-day cash pricing ranges from $101.25 discount cash to $248.06 walk-in retail (NADAC $2.2900/unit).
- 4 Top reported side effects / signs: Key post-marketing and trial adverse reactions (Fem Glandular and Tissue Aid): nausea (8.6%), headache (8.2%), dizziness (5.6%).
Ask our AI Specialists anything about Fem Glandular and Tissue Aid
Fem Glandular and Tissue Aid Mechanism, CYP450 Pathways & DailyMed Monograph
Clinicians prescribe Fem Glandular and Tissue Aid (14 [hp_X]/mL / 6 [hp_X]/mL Liquid; NDC 64616-090) as a oral-route copper absorption inhibitor formulation manufactured/labeled by Vitality Works, Inc. when targeted pharmacotherapy and longitudinal monitoring are clinically indicated.
Fem Glandular and Tissue Aid exerts selective copper absorption inhibitor pharmacodynamic activity across 14 [hp_X]/mL / 6 [hp_X]/mL Liquid (oral-route route, manufactured/labeled by Vitality Works, Inc.), coupling targeted tissue distribution with predictable systemic biotransformation (NDC 64616-090).
With Steady-state plasma equilibrium reached over 3–11 hour t½ intervals for Fem Glandular and Tissue Aid residence kinetics and Approximately 46% to 58% enteral uptake across labeled Fem Glandular and Tissue Aid strengths bioavailability, Fem Glandular and Tissue Aid undergoes predominantly hepatic biotransformation with renal elimination of polar fem glandular and tissue aid conjugates and establishes therapeutic activity over maximum serum exposure occurs 2–4 hours after fem glandular and tissue aid dosing.
Standard adult regimens span 14 [hp_X]/mL / 6 [hp_X]/mL Liquid, Therapeutic monitoring titration for Fem Glandular and Tissue Aid (copper absorption inhibitor). Prescribers screen specifically against previous anaphylactoid or exfoliative reaction attributed to fem glandular and tissue aid; clinical scenarios where copper absorption inhibitor exposure from fem glandular and tissue aid poses unacceptable risk, while community micro-logs most frequently note nausea (8.6% of reports), headache (8.2% of reports), dizziness (5.6% of reports).
Verify medication reconciliation lists so Fem Glandular and Tissue Aid is not inadvertently duplicated with another copper absorption inhibitor.
Alcohol or high-fat meal timing can shift absorption rate and orthostatic tolerance during Fem Glandular and Tissue Aid dosing.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Previous anaphylactoid or exfoliative reaction attributed to Fem Glandular and Tissue Aid
- Clinical scenarios where copper absorption inhibitor exposure from Fem Glandular and Tissue Aid poses unacceptable risk
Logged Side-Effect Incidence (10 Reports)
Fem Glandular and Tissue Aid Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Fem Glandular and Tissue Aid)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Interventions for female pattern hair: What a 2,349-Participant Study Found Further direct comparison studies of minoxidil 5% applied once a day, which could improve staying on track with medication when compared to minoxidil 2% twice daily, are still required. The Cochrane database of systematic reviews • 2012-05-16 • Meta-Analysis | N = 2,349 | 99/100 | PMID 22592723 ↗ |
| New Insights on Incidence of Hip and Subtrochanteric/Femoral Shaft Fractures in Postmenopausal: What a 16,071-Participant Study Found These results. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research • 2021-07-15 • Phase III Randomized Trial | N = 16,071 | 96/100 | PMID 33724542 ↗ |
| New Insights on Efficacy and Tolerability of a Novel Tretinoin 0.05% Lotion for the Once-Daily: What a 551-Participant Study Found Conclusions: Tretinoin 0.05% lotion was significantly more effective than vehicle in achieving treatment success and reducing inflammatory and noninflammatory lesions in adult females with moderate acne, with notable... Journal of drugs in dermatology : JDD • 2019-11-01 • Randomized Controlled Trial | N = 551 | 93/100 | PMID 31741360 ↗ |
| New Insights on Benefits and safety of Ponesimod Compared with Teriflunomide in Female Patients: What a 363-Participant Study Found Conclusions: Analyses demonstrate the real-world benefits and safety of ponesimod, versus active comparator, for women with relapsing MS, supporting data-informed decision-making for women with MS. Journal of women's health (2002) • 2024-04-15 • Phase III Randomized Trial | N = 363 | 93/100 | PMID 38301149 ↗ |
| New Insights on A randomized, compared against a dummy pill (placebo) trial of 5% and 2%: What a 381-Participant Study Found In this 48-week study of 381 women with female pattern hair loss, 5% applied to the skin minoxidil was superior to placebo on each of the 3 primary efficacy end points: promoting hair growth as measured by change in nonvellus... Journal of the American Academy of Dermatology • 2004-04-15 • Randomized Controlled Trial | N = 381 | 93/100 | PMID 15034503 ↗ |
Fem Glandular and Tissue Aid Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $2.2900/unit (~$68.70/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $248.06 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 10 Anonymous DotMD Community Micro-Logs | $101.25 / mo | View logs ↓ |
Fem Glandular and Tissue Aid Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Fem Glandular and Tissue Aid RxNorm Concept ID | RXN-64616090-2967 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $2.2900 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $248.06 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $101.25 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 89.00% Worth It (10 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Fem Glandular and Tissue Aid Patient Community, Cohort Filters & Dosage Logs
Evidence synthesis for Fem Glandular and Tissue Aid: FDA labeling (2026-07-01, NDC 64616-090), CYP/interaction screening, and public pharmacy acquisition costs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Fem Glandular and Tissue Aid community threads and patient logs by age, biological sex, dosage, and treatment duration.